These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
160 related articles for article (PubMed ID: 1740413)
21. Site-directed mutagenesis of arginine 103 and lysine 185 in the proposed glycosaminoglycan-binding site of heparin cofactor II. Blinder MA; Tollefsen DM J Biol Chem; 1990 Jan; 265(1):286-91. PubMed ID: 2104620 [TBL] [Abstract][Full Text] [Related]
22. Allosteric changes in thrombin's activity produced by peptides corresponding to segments of natural inhibitors and substrates. Hortin GL; Trimpe BL J Biol Chem; 1991 Apr; 266(11):6866-71. PubMed ID: 1849894 [TBL] [Abstract][Full Text] [Related]
23. Comparison of heparin- and dermatan sulfate-mediated catalysis of thrombin inactivation by heparin cofactor II. Liaw PC; Austin RC; Fredenburgh JC; Stafford AR; Weitz JI J Biol Chem; 1999 Sep; 274(39):27597-604. PubMed ID: 10488098 [TBL] [Abstract][Full Text] [Related]
24. Allosteric changes of thrombin catalytic site induced by interaction of bothrojaracin with anion-binding exosites I and II. Monteiro RQ; Rapôso JG; Wisner A; Guimarães JA; Bon C; Zingali RB Biochem Biophys Res Commun; 1999 Sep; 262(3):819-22. PubMed ID: 10471408 [TBL] [Abstract][Full Text] [Related]
25. Mechanism of thrombin inhibition by antithrombin and heparin cofactor II in the presence of heparin. Maaroufi RM; Jozefowicz M; Tapon-Bretaudière J; Fischer AM Biomaterials; 1997 Feb; 18(3):203-11. PubMed ID: 9031720 [TBL] [Abstract][Full Text] [Related]
26. Mechanism of thrombin inhibition by heparin cofactor II in the presence of dermatan sulphates, native or oversulphated, and a heparin-like dextran derivative. Maaroufi RM; Jozefowicz M; Tapon-Bretaudière J; Jozefonvicz J; Fischer AM Biomaterials; 1997 Feb; 18(4):359-66. PubMed ID: 9068899 [TBL] [Abstract][Full Text] [Related]
27. Structural and functional properties of human alpha-thrombin, phosphopyridoxylated alpha-thrombin, and gamma T-thrombin. Identification of lysyl residues in alpha-thrombin that are critical for heparin and fibrin(ogen) interactions. Church FC; Pratt CW; Noyes CM; Kalayanamit T; Sherrill GB; Tobin RB; Meade JB J Biol Chem; 1989 Nov; 264(31):18419-25. PubMed ID: 2509458 [TBL] [Abstract][Full Text] [Related]
28. Characterization of recombinant heparin cofactor II expressed in insect cells. Ciaccia AV; Cunningham EL; Church FC Protein Expr Purif; 1995 Dec; 6(6):806-12. PubMed ID: 8746633 [TBL] [Abstract][Full Text] [Related]
29. Interaction of heparin cofactor II with neutrophil elastase and cathepsin G. Pratt CW; Tobin RB; Church FC J Biol Chem; 1990 Apr; 265(11):6092-7. PubMed ID: 2318847 [TBL] [Abstract][Full Text] [Related]
30. Antithrombin activity of fucoidan. The interaction of fucoidan with heparin cofactor II, antithrombin III, and thrombin. Church FC; Meade JB; Treanor RE; Whinna HC J Biol Chem; 1989 Feb; 264(6):3618-23. PubMed ID: 2914965 [TBL] [Abstract][Full Text] [Related]
31. [The antithrombin action of stichopus japonicus acid mucopolysaccharide (Sjamp) is mediated by heparin cofactor II]. Zhang G Zhonghua Xue Ye Xue Za Zhi; 1997 Mar; 18(3):126-9. PubMed ID: 15622771 [TBL] [Abstract][Full Text] [Related]
32. Modulation of the enzymatic activity of alpha-thrombin by polyanions: consequences on intrinsic activation of factor V and factor VIII. Ofosu FA Haemostasis; 1991; 21(4):240-7. PubMed ID: 1794749 [TBL] [Abstract][Full Text] [Related]
33. The complete N-terminal extension of heparin cofactor II is required for maximal effectiveness as a thrombin exosite 1 ligand. Boyle AJ; Roddick LA; Bhakta V; Lambourne MD; Junop MS; Liaw PC; Weitz JI; Sheffield WP BMC Biochem; 2013 Mar; 14():6. PubMed ID: 23496873 [TBL] [Abstract][Full Text] [Related]
34. Binding of heparin or dermatan sulfate to thrombin is essential for the sulfated polysaccharide-accelerated inhibition of thrombin by heparin cofactor II. Yamagishi R; Koide T; Sakuragawa N FEBS Lett; 1987 Dec; 225(1-2):109-12. PubMed ID: 3691797 [TBL] [Abstract][Full Text] [Related]
35. Bifunctional peptide boronate inhibitors of thrombin: crystallographic analysis of inhibition enhanced by linkage to an exosite 1 binding peptide. Skordalakes E; Elgendy S; Goodwin CA; Green D; Scully MF; Kakkar VV; Freyssinet JM; Dodson G; Deadman JJ Biochemistry; 1998 Oct; 37(41):14420-7. PubMed ID: 9772168 [TBL] [Abstract][Full Text] [Related]
36. RNA aptamer to thrombin binds anion-binding exosite-2 and alters protease inhibition by heparin-binding serpins. Jeter ML; Ly LV; Fortenberry YM; Whinna HC; White RR; Rusconi CP; Sullenger BA; Church FC FEBS Lett; 2004 Jun; 568(1-3):10-4. PubMed ID: 15196911 [TBL] [Abstract][Full Text] [Related]
38. Chimeric antithrombin peptide. Characterization of an Arg-Gly-Asp (RGD)- and hirudin carboxyl terminus-containing synthetic peptides. Church FC; Phillips JE; Woods JL J Biol Chem; 1991 Jun; 266(18):11975-9. PubMed ID: 2050691 [TBL] [Abstract][Full Text] [Related]
39. A new class of potent thrombin inhibitors that incorporates a scissile pseudopeptide bond. DiMaio J; Ni F; Gibbs B; Konishi Y FEBS Lett; 1991 Apr; 282(1):47-52. PubMed ID: 2026264 [TBL] [Abstract][Full Text] [Related]
40. Mechanism of potentiation of antithrombin III and heparin cofactor II inhibition by sulfated xylans. Carson L; Doctor VM Thromb Res; 1990 May; 58(4):367-81. PubMed ID: 1972302 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]